Cargando…
Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial
AIM: The neural cardiac therapy for heart failure (NECTAR-HF) was a randomized sham-controlled trial designed to evaluate whether a single dose of vagal nerve stimulation (VNS) would attenuate cardiac remodelling, improve cardiac function and increase exercise capacity in symptomatic heart failure p...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4328197/ https://www.ncbi.nlm.nih.gov/pubmed/25176942 http://dx.doi.org/10.1093/eurheartj/ehu345 |
_version_ | 1782357204146323456 |
---|---|
author | Zannad, Faiez De Ferrari, Gaetano M. Tuinenburg, Anton E. Wright, David Brugada, Josep Butter, Christian Klein, Helmut Stolen, Craig Meyer, Scott Stein, Kenneth M. Ramuzat, Agnes Schubert, Bernd Daum, Doug Neuzil, Petr Botman, Cornelis Castel, Maria Angeles D'Onofrio, Antonio Solomon, Scott D. Wold, Nicholas Ruble, Stephen B. |
author_facet | Zannad, Faiez De Ferrari, Gaetano M. Tuinenburg, Anton E. Wright, David Brugada, Josep Butter, Christian Klein, Helmut Stolen, Craig Meyer, Scott Stein, Kenneth M. Ramuzat, Agnes Schubert, Bernd Daum, Doug Neuzil, Petr Botman, Cornelis Castel, Maria Angeles D'Onofrio, Antonio Solomon, Scott D. Wold, Nicholas Ruble, Stephen B. |
author_sort | Zannad, Faiez |
collection | PubMed |
description | AIM: The neural cardiac therapy for heart failure (NECTAR-HF) was a randomized sham-controlled trial designed to evaluate whether a single dose of vagal nerve stimulation (VNS) would attenuate cardiac remodelling, improve cardiac function and increase exercise capacity in symptomatic heart failure patients with severe left ventricular (LV) systolic dysfunction despite guideline recommended medical therapy. METHODS: Patients were randomized in a 2 : 1 ratio to receive therapy (VNS ON) or control (VNS OFF) for a 6-month period. The primary endpoint was the change in LV end systolic diameter (LVESD) at 6 months for control vs. therapy, with secondary endpoints of other echocardiography measurements, exercise capacity, quality-of-life assessments, 24-h Holter, and circulating biomarkers. RESULTS: Of the 96 implanted patients, 87 had paired datasets for the primary endpoint. Change in LVESD from baseline to 6 months was −0.04 ± 0.25 cm in the therapy group compared with −0.08 ± 0.32 cm in the control group (P = 0.60). Additional echocardiographic parameters of LV end diastolic dimension, LV end systolic volume, left ventricular end diastolic volume, LV ejection fraction, peak V0(2), and N-terminal pro-hormone brain natriuretic peptide failed to show superiority compared to the control group. However, there were statistically significant improvements in quality of life for the Minnesota Living with Heart Failure Questionnaire (P = 0.049), New York Heart Association class (P = 0.032), and the SF-36 Physical Component (P = 0.016) in the therapy group. CONCLUSION: Vagal nerve stimulation as delivered in the NECTAR-HF trial failed to demonstrate a significant effect on primary and secondary endpoint measures of cardiac remodelling and functional capacity in symptomatic heart failure patients, but quality-of-life measures showed significant improvement. |
format | Online Article Text |
id | pubmed-4328197 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-43281972015-02-26 Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial Zannad, Faiez De Ferrari, Gaetano M. Tuinenburg, Anton E. Wright, David Brugada, Josep Butter, Christian Klein, Helmut Stolen, Craig Meyer, Scott Stein, Kenneth M. Ramuzat, Agnes Schubert, Bernd Daum, Doug Neuzil, Petr Botman, Cornelis Castel, Maria Angeles D'Onofrio, Antonio Solomon, Scott D. Wold, Nicholas Ruble, Stephen B. Eur Heart J FASTTrack Esc Hot Line AIM: The neural cardiac therapy for heart failure (NECTAR-HF) was a randomized sham-controlled trial designed to evaluate whether a single dose of vagal nerve stimulation (VNS) would attenuate cardiac remodelling, improve cardiac function and increase exercise capacity in symptomatic heart failure patients with severe left ventricular (LV) systolic dysfunction despite guideline recommended medical therapy. METHODS: Patients were randomized in a 2 : 1 ratio to receive therapy (VNS ON) or control (VNS OFF) for a 6-month period. The primary endpoint was the change in LV end systolic diameter (LVESD) at 6 months for control vs. therapy, with secondary endpoints of other echocardiography measurements, exercise capacity, quality-of-life assessments, 24-h Holter, and circulating biomarkers. RESULTS: Of the 96 implanted patients, 87 had paired datasets for the primary endpoint. Change in LVESD from baseline to 6 months was −0.04 ± 0.25 cm in the therapy group compared with −0.08 ± 0.32 cm in the control group (P = 0.60). Additional echocardiographic parameters of LV end diastolic dimension, LV end systolic volume, left ventricular end diastolic volume, LV ejection fraction, peak V0(2), and N-terminal pro-hormone brain natriuretic peptide failed to show superiority compared to the control group. However, there were statistically significant improvements in quality of life for the Minnesota Living with Heart Failure Questionnaire (P = 0.049), New York Heart Association class (P = 0.032), and the SF-36 Physical Component (P = 0.016) in the therapy group. CONCLUSION: Vagal nerve stimulation as delivered in the NECTAR-HF trial failed to demonstrate a significant effect on primary and secondary endpoint measures of cardiac remodelling and functional capacity in symptomatic heart failure patients, but quality-of-life measures showed significant improvement. Oxford University Press 2015-02-14 2014-08-31 /pmc/articles/PMC4328197/ /pubmed/25176942 http://dx.doi.org/10.1093/eurheartj/ehu345 Text en © The Author 2014. Published by Oxford University Press on behalf of the European Society of Cardiology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | FASTTrack Esc Hot Line Zannad, Faiez De Ferrari, Gaetano M. Tuinenburg, Anton E. Wright, David Brugada, Josep Butter, Christian Klein, Helmut Stolen, Craig Meyer, Scott Stein, Kenneth M. Ramuzat, Agnes Schubert, Bernd Daum, Doug Neuzil, Petr Botman, Cornelis Castel, Maria Angeles D'Onofrio, Antonio Solomon, Scott D. Wold, Nicholas Ruble, Stephen B. Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial |
title | Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial |
title_full | Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial |
title_fullStr | Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial |
title_full_unstemmed | Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial |
title_short | Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial |
title_sort | chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the neural cardiac therapy for heart failure (nectar-hf) randomized controlled trial |
topic | FASTTrack Esc Hot Line |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4328197/ https://www.ncbi.nlm.nih.gov/pubmed/25176942 http://dx.doi.org/10.1093/eurheartj/ehu345 |
work_keys_str_mv | AT zannadfaiez chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial AT deferrarigaetanom chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial AT tuinenburgantone chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial AT wrightdavid chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial AT brugadajosep chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial AT butterchristian chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial AT kleinhelmut chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial AT stolencraig chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial AT meyerscott chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial AT steinkennethm chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial AT ramuzatagnes chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial AT schubertbernd chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial AT daumdoug chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial AT neuzilpetr chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial AT botmancornelis chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial AT castelmariaangeles chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial AT donofrioantonio chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial AT solomonscottd chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial AT woldnicholas chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial AT rublestephenb chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial |